The global peptide antibiotics market was valued at around US$ 4.4 Billion at the end of 2021. The market is projected to register a 6.6% CAGR and top a valuation of US$ 8.3 Billion by 2032.
The market for peptide antibiotics is likely to thrive in the future given the rising incidence of disorders such as bloodstream infections, hospital-acquired infections, and bacterial skin infections.
Peptide antibiotics are peptides having strong antibacterial and antifungal properties. Peptide antibiotics are an essential part of the innate immune system, which living organisms rely on as their first line of defense against invading pathogens. The primary sites for the synthesis of these peptides are tissues that have direct environmental contact, such as the skin, gut, and lungs.
Peptide antibiotics are anti-infective and anti-tumor medicines that contain polypeptide chains. Peptide antibiotics come in two varieties: ribosomally synthesized peptide antibiotics and non-ribosomally synthesized peptide antibiotics. The advantages of peptide antibiotics include high specificity, high efficacy, and low toxicity.
| Attributes | Details |
|---|---|
| Peptide Antibiotics Market Value in 2021 | US$ 4.4 Billion |
| Peptide Antibiotics Market Value in 2032 | US$ 8.3 Billion |
| Peptide Antibiotics Market CAGR (2022 to 2032) | 6.6% |
In light of factors like rising peptide antibiotic research & development activity and a high number of product approvals, the market is anticipated to experience potential growth. Additionally, the potential for side effects from traditional antibiotics and the rise in occurrences of antimicrobial resistance are anticipated to fuel the market throughout the forecast period.
Over the projected period, rising rates of cancer and other related infections are expected to spur growth. Some peptide antibiotics are prescribed to treat malignancies such as Hodgkin's lymphoma and a few different kinds of skin cancers. Globocan 2020 reports that there were 83,087 instances of Hodgkin's lymphoma and 5,44,352 cases of non-Hodgkin lymphoma. Due to doctor recommendations, it is anticipated that the effectiveness of various existing products would result in higher sales. BLEOMYCIN for injection is a combination of cytotoxic glycopeptide antibiotics, which is derived from the bacterium Streptomyces verticillus. It is utilized for the treatment of testicular cancer, squamous cell carcinoma, and other types of lymphomas.
The peptide antibiotics market is broadly divided into seven major regions, North America, Latin America, Europe, East Asia, South Asia, Oceania, and the Middle East and Africa.
The largest market for peptide antibiotics is in North America. Increased Research and Development activities in the region are anticipated to fuel the market over the projected period due to the region's increased demand for antibiotics.
The European peptide antibiotics industry is likewise anticipated to experience profitable expansion. Some of the important drivers of growth are the existence of major manufacturers and strategic initiatives undertaken by prominent companies.
The East Asian region is predicted to show lucrative growth owing to increasing rates of infectious disease and the vast presence of the elderly population.
Pfizer Inc., Merck & Co., Inc., AbbVie Inc, GSK Group of Companies, Sandoz International GmbH, Xellia Pharmaceuticals, AuroMedics Pharma LLC, Theravance Biopharma, Novartis, GlaxoSmithKline, Eli Lilly.
| Report Attributes | Details |
|---|---|
| Growth Rate | CAGR of 6.6% from 2022 to 2032 |
| Base Year for Estimation | 2021 |
| Historical Data | 2012 to 2021 |
| Forecast Period | 2022 to 2032 |
| Qualitative Units | Revenue in USD Billion, and CAGR from 2022 to 2032 |
| Report Coverage | Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, and Trends |
| Segment Covered | Product, Disease, Route of Administration, Distribution Channel, Region |
| Region Covered | North America; Latin America; Europe; East Asia; South Asia; Oceania; Middle East & Africa |
| Key Countries Profiled | USA, Canada, Brazil, Mexico, Germany, UK, France, Spain, Italy, China, Japan, South Korea, Malaysia, Singapore, Australia, New Zealand, GCC Countries, South Africa, Israel |
| Key Players | Pfizer Inc.; Merck & Co., Inc.; AbbVie Inc; GSK Group of Companies; Sandoz International GmbH; Xellia Pharmaceuticals; AuroMedics Pharma LLC; Theravance Biopharma; Novartis; GlaxoSmithKline; Eli Lilly |
| Customization | Available Upon Request |
The global peptide antibiotics market is anticipated to register a CAGR of 6.6% during the forecast period.
The global peptide antibiotics market is projected to be about US$ 8.3 Billion by the end of the year 2032.
Explore Similar Insights
Peptide Antibiotics Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
